Telmisartan prevents the glitazone-induced weight gain without interfering with its insulin-sensitizing properties

American Journal of Physiology - Endocrinology and Metabolism

Volumn 293, Issue 1, 2007, Pages

  Zanchi, Anne ^a   Dulloo, Abdul G ^b   Perregaux, Christine ^a   Montani, Jean Pierre ^b   Burnier, Michel ^a  

^a LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

^b UNIVERSITY OF FRIBOURG   (Switzerland)

Author keywords

Angiotensin II receptor blocker; Fat; Glitazones

Indexed keywords

GLITAZONE DERIVATIVE; INSULIN; PIOGLITAZONE; TELMISARTAN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BODY WEIGHT; CONTROLLED STUDY; DISEASE MODEL; DRUG EFFECT; INSULIN RESISTANCE; INSULIN SENSITIVITY; MALE; NONHUMAN; OBESITY; PRIORITY JOURNAL; RAT; SPRAGUE DAWLEY RAT; TREATMENT DURATION; WEIGHT GAIN; ZUCKER RAT;

ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANIMALS; BENZIMIDAZOLES; BENZOATES; DRUG EVALUATION, PRECLINICAL; DRUG INTERACTIONS; INSULIN; INSULIN RESISTANCE; MALE; OBESITY; RATS; RATS, SPRAGUE-DAWLEY; RATS, ZUCKER; THIAZOLIDINEDIONES; WEIGHT GAIN;

EID: 34547110780     PISSN: 01931849     EISSN: 15221555     Source Type: Journal    
DOI: 10.1152/ajpendo.00024.2007     Document Type: Article

References (18)

1. Benson SC, Pershadsingh HA, Ho CI, Chittiboyina A, Desai P, Pravenec M, Qi N, Wang J, Avery MA, Kurtz TW. Identification of telmisartan as a unique angiotensin II receptor antagonist with selective PPARgammamodulating activity. Hypertension 43: 993-1002, 2004.
2. Burnier M, Zanchi A. Blockade of the renin-angiotensin-aldosterone system: a key therapeutic strategy to reduce renal and cardiovascular events in patients with diabetes. J Hypertens 24: 11-25, 2006.
3. Chiquette E, Ramirez G, Defronzo R. A meta-analysis comparing the effect of thiazolidinediones on cardiovascular risk factors. Arch Intern Med 164: 2097-2104, 2004.
4. Dulloo AG, Girardier L. Adaptive changes in energy expenditure during refeeding following low-calorie intake: evidence for a specific metabolic component favoring fat storage. Am J Clin Nutr 52: 415-420, 1990.
5. Entenman C. General Procedures for Separating Components of Tissue, edited by Colowick SP and Kaplan O. City, State: Publisher, 1957.
6. Fonseca V. Effect of thiazolidinediones on body weight in patients with diabetes mellitus. Am J Med 115, Suppl 8A: 42S-48S, 2003.
7. Larsen PJ, Jensen PB, Sorensen RV, Larsen LK, Vrang N, Wulff EM, Wassermann K. Differential influences of peroxisome proliferator-activated receptors gamma and alpha on food intake and energy homeostasis. Diabetes 52: 2249-2259, 2003.
8. Maillard MP, Perregaux C, Centeno C, Stangier J, Wienen W, Brunner HR, Burnier M. In vitro and in vivo characterization of the activity of telmisartan: an insurmountable angiotensin II receptor antagonist. J Pharmacol Exp Ther 302: 1089-1095, 2002.
9. Mather K, Hunt A, Steinberg H, Paradisi G, Hook G, Katz A, Quon M, Baron A. Repeatability characteristics of simple indices of insulin resistance: implications for research applications. J Clin Endocrinol Metab 86: 5457-5464, 2001.
10. Miller DS, Payne PR. A ballistic bomb calorimeter. Br J Nutr 13: 501-508, 1959.
11. Schupp M, Clemenz M, Gineste R, Witt H, Janke J, Helleboid S, Hennuyer N, Ruiz P, Unger T, Staels B, Kintscher U. Molecular characterization of new selective peroxisome proliferator-activated receptor γ modulators with angiotensin receptor blocking activity. Diabetes 54: 3442-3452, 2005.
12. Schupp M, Janke J, Clasen R, Unger T, Kintscher U. Angiotensin type 1 receptor blockers induce peroxisome proliferator-activated receptor-gamma activity. Circulation 109: 2054-2057, 2004.
13. Smith SR, De Jonge L, Volaufova J, Li Y, Xie H, Bray GA. Effect of pioglitazone on body composition and energy expenditure: a randomized controlled trial. Metabolism 54: 24-32, 2005.
14. Sugimoto K, Qi NR, Kazdova L, Pravenec M, Ogihara T, Kurtz TW. Telmisartan but not valsartan increases caloric expenditure and protects against weight gain and hepatic steatosis. Hypertension 47: 1003-1009, 2006.
15. Yki-Jarvinen H. Thiazolidinediones. N Engl J Med 351: 1106-1118, 2004.
16. Zanchi A, Aubert JF, Brunner HR, Waeber B. Vascular acetylcholine response during chronic NO synthase inhibition: in vivo versus in vitro. Cardiovasc Res 30: 122-129, 1995.
17. Zanchi A, Chiolero A, Maillard M, Nussberger J, Brunner HR, Burnier M. Effects of the peroxisomal proliferator-activated receptor-gamma agonist pioglitazone on renal and hormonal responses to salt in healthy men. J Clin Endocrinol Metab 89: 1140-1145, 2004.
18. Zanchi A, Perregaux C, Maillard M, Cefai D, Nussberger J, Burnier M. The PPAR-γ agonist pioglitazone modifies the vascular sodium-angiotensin II relationship in insulin-resistant rats. Am J Physiol Endocrinol Metab 291: E1228-E1234, 2006.